Unique ID issued by UMIN | UMIN000032040 |
---|---|
Receipt number | R000036556 |
Scientific Title | The exploratory study on change of the gutmicrobiota in Rabeprazole divided doses:Direction crossover controlled trial in front of an open label |
Date of disclosure of the study information | 2018/04/01 |
Last modified on | 2021/05/09 11:57:20 |
The exploratory study on change of the gutmicrobiota in Rabeprazole divided doses:Direction crossover controlled trial in front of an open label
The exploratory study on change of the gutmicrobiota in the Rabeprazole administration
The exploratory study on change of the gutmicrobiota in Rabeprazole divided doses:Direction crossover controlled trial in front of an open label
The exploratory study on change of the gutmicrobiota in the Rabeprazole administration
Japan |
Reflux esophagitis.
Gastroenterology |
Others
NO
The aim of this study was to determine the association between intragastric pH and change of the intestinal bacterial flora by changing the proton pump inhibitor doses.
Efficacy
Correlation of intragastric pH and enteric bacteria profile.
Interventional
Cross-over
Non-randomized
Open -no one is blinded
Dose comparison
NO
NO
3
Treatment
Device,equipment |
Subjects are 12 Helicobacter pylori infection-negative healthy Volunteers.Subjects take rabeprazole 10 mg o.d for 7 days. We conduct examination of 24 hours pH monitoring and flora sampling on the seventh day.
Subjects are 12 Helicobacter pylori infection-negative healthy Volunteers.Subjects take rabeprazole 5mg o.d for 7 days. We conduct examination of 24 hours pH monitoring and flora sampling on the seventh day.
Subjects are 12 Helicobacter pylori infection-negative healthy Volunteers.Subjects take rabeprazole 5mg bid for 7 days. We conduct examination of 24 hours pH monitoring and flora sampling on the seventh day.
20 | years-old | <= |
50 | years-old | >= |
Male and Female
1.With consent
2.From 20 years old to 50 years old.
2.H.pylori infection-negative.
3.Performance status:ECOG 0.
1.No consent
2.With the drug including a suppressant acid-secreting for the past one month.
3.With probiotics (medicine for intestinal disorders) or the antimicrobial agent for the past one month.
4.With grapefruits for the past two weeks.
5.With operating treatment for upper gastrointestinal disease including esophagus and stomach.
6.During pregnancy or nursing.
12
1st name | |
Middle name | |
Last name | Mitsushige Sugimoto |
Shiga University of Medical Science Hospital
Division of Digestive Endoscopy
Seta Tsukinowa-cho, Otsu, Shiga, JAPAN,520-2192
077-548-2618
sugimo@belle.shiga-med.ac.jp
1st name | |
Middle name | |
Last name | Mitsushige Sugimoto |
Shiga University of Medical Science Hospital
Division of Digestive Endoscopy
Seta Tsukinowa-cho, Otsu, Shiga, JAPAN,520-2192
077-548-2618
sugimo@belle.shiga-med.ac.jp
Shiga University of Medical Science
Shiga University of Medical Science
Self funding
NO
2018 | Year | 04 | Month | 01 | Day |
Unpublished
Completed
2018 | Year | 03 | Month | 29 | Day |
2018 | Year | 03 | Month | 29 | Day |
2018 | Year | 03 | Month | 29 | Day |
2019 | Year | 03 | Month | 31 | Day |
2018 | Year | 03 | Month | 31 | Day |
2021 | Year | 05 | Month | 09 | Day |
Value
https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000036556
Research Plan | |
---|---|
Registered date | File name |
Research case data specifications | |
---|---|
Registered date | File name |
Research case data | |
---|---|
Registered date | File name |